Inherited retinal disease-associated uveitis
- PMID: 40157547
- DOI: 10.1016/j.survophthal.2025.03.011
Inherited retinal disease-associated uveitis
Abstract
Inherited retinal diseases (IRDs) are genetic disorders characterized by progressive photoreceptor function loss, often leading to significant visual impairment. Uveitis has been increasingly recognized in the clinical course of some IRDs. Despite advances in understanding the genetic causes and pathophysiology of IRDs, gaps remain in understanding the roles of inflammation and autoimmunity in IRD and IRD-associated uveitis. This review discusses IRD-associated uveitis, including anterior, intermediate, posterior, and panuveitis, as well as complications such as cystoid macular edema and retinal vasculitis. In patients with IRD-associated uveitis, mutations affecting protein function in cilia or photoreceptor outer segments suggest a universal autoimmune mechanism triggered by the immunogenicity of shedding photoreceptor discs. Notably, in patients where uveitis is the initial sign, CRB1 mutations are often implicated, likely due to the compromised blood-retina barrier function or alterations in the external limiting membrane. Other mechanisms leading to uveitis preceding IRD diagnosis include ALPK1 mutations, which activate the proinflammatory NF-κB pathway, CAPN5 mutations, which lead to dysfunction of the innate and adaptive immune systems, and VCAN1 mutations, which elicit immunogenicity due to irregularities in vitreous modeling. Understanding these mechanisms could enhance the development of innovative treatments that target personalized inflammation pathways in IRDs.
Keywords: Anterior uveitis; Cystoid macular edema; Inherited retinal disease; Intermediate uveitis; Panuveitis; Posterior uveitis; Retinal vasculitis; Retinitis pigmentosa.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Quan Dong Nguyen reports a relationship with Affibody Medical AB that includes: board membership. Quan Dong Nguyen reports a relationship with ACELYRIN Inc that includes: board membership. Quan Dong Nguyen reports a relationship with Genentech that includes: board membership. Quan Dong Nguyen reports a relationship with Priovant Therapeutics, Inc. that includes: board membership. Quan Dong Nguyen reports a relationship with Regeneron Pharmaceuticals Inc that includes: board membership. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Conflicts of interest Dr. Quan Dong Nguyen has chaired the Steering Committees for the SAKURA, VISUAL, STOP-Uveitis, LINNAEA, LEOPARD studies. Dr. Nguyen also serves on Scientific Advisory Boards for Affibody, Acelyrin, Genentech, Oculis, Priovant, and Regeneron, among others. No conflict of interest exists for any of the other authors.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
